Santaris Pharma - Gilde Healthcare

Venture&Growth

All Portfolio items

Location

Hørsholm, Denmark
San Diego (CA), USA

RNA-targeted Therapies

Since: 2007

Exit: 2014

Santaris Pharma

Venture&Growth

All Portfolio items

See full Venture&Growth portfolio

Santaris Pharma discovers and develops RNA-targeted therapies to treat infectious diseases and metabolic disorders. Through its partnerships with pharmaceutical companies, Santaris covers a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders.

Since Gilde invested in Santaris Pharma, the company has advanced its product pipeline through the clinic and signed commercial collaboration agreements with GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Roche and Shire. Santaris Pharma was acquired by Roche in 2014 for $450M.

Continue reading on Roche.com: Locked Nucleic Acid (LNA) Platform

More Santaris Pharma news

Successful Exit Gilde Healthcare Following Sale of Danish Biopharmaceutical Company Santaris

August 6, 2014

Santaris Pharma A/S signs partnership with RaNA Therapeutics, Inc.

July 11, 2013

Santaris announces Strategic Alliance with Bristol-Myers Squibb

April 17, 2013

Santaris Pharma A/S – The New England Journal of Medicine Publishes Marked and Long-Lasting Antivira

March 27, 2013

Santaris Pharma A/S advances the first microRNA-targeted drug to Phase 2 to treat Hepatitis C

November 8, 2011

SANTARIS PHARMA advances RNA-targeted drug development candidate against PCSK9

April 26, 2010

SANTARIS PHARMA – New data show breakthrough microRNA-targeted therapy

December 3, 2009

New collaborations and breakthrough advancements in RNA-based drug development programs

September 16, 2009

Santaris Pharma A/S forms strategic alliance with Shire plc to develop RNA-based medicines

August 24, 2009

SANTARIS – LNA-based HIF-1 alpha inhibitor shows early signs of clinical benefit

June 4, 2009

Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines

January 12, 2009

Santaris Pharma Appoints Søren Tulstrup as New President & CEO

June 19, 2008

All Santaris Pharma news

More Venture&Growth Companies

All companies